Bolt Biotherapeutics has been a clinical-stage biotechnology firm with a historical emphasis on immuno-oncology via its Boltbody ISAC platform. After the October 2026 reverse merger with Prana Therapies, the focus has moved to Prana's INSPIRE platform, which develops half-life-extended, fully IgG-based multispecific antibodies.
The combined entity's lead asset is PRA-216, an IL-4Rα/TSLP bispecific antibody now in Phase 2 for asthma, COPD, and atopic dermatitis, with another Phase 2 study planned in eosinophilic esophagitis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors see exposure here to sizable inflammatory-disease markets and a pipeline aimed at strong efficacy with convenient subcutaneous dosing.
In the last 30 days, BOLT gained approximately 52%, advancing from a mid-October close near $4.00 to about $6.08 by mid-November. Most of the increase came in one session on October 23, 2026, when shares rose roughly 62% on higher volume after the merger and financing news.
The quarterly view shows similar strength. From roughly $3.20 in mid-August, the stock reached around $6.08, for a gain of about 85%. It had traded in a tight band between roughly $3.10 and $4.20 through much of the summer and early fall before the transaction news prompted a clear re-rating.
The main driver was the October 23, 2026 announcement that Bolt completed a sign-and-close reverse merger to acquire Prana Therapies, alongside a private placement targeting $120 million in gross proceeds and up to $60 million more from warrant exercises.
Prana equity holders received Bolt common stock and Series D non-voting convertible preferred stock. On a fully diluted basis, post-transaction ownership breaks down to about 6.9% for pre-deal Bolt holders, 51.7% for former Prana holders, and 41.4% for private-placement investors. The syndicate featured healthcare specialists including Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Eventide Asset Management, Casdin Capital, and Soleus Capital.
The reaction centered on the strategic shift rather than earnings. The merger adds Prana's INSPIRE platform and PRA-216, placing Bolt in immunology assets with large markets and several Phase 2 readouts ahead. Dr. Sheila Gujrathi joined the board as Chief Strategy Officer, while Willie Quinn remains CEO.
For much of the quarter, BOLT moved in a limited range amid a modest cash position and few near-term catalysts from the prior oncology pipeline. By mid-2026, limited cash and strategic uncertainty weighed on sentiment.
The Prana reverse merger changed that outlook. Acquiring a clinical-stage platform in inflammatory and allergic diseases, plus the concurrent financing, transformed the pipeline and extended the runway into 2028 to cover PRA-216 Phase 2 milestones. This new asset mix, stronger balance sheet, and active 2027 clinical schedule supported the multi-month re-rating.
Looking forward, attention centers on PRA-216 clinical updates. Proof-of-concept data from the asthma, COPD, atopic dermatitis, and eosinophilic esophagitis studies is expected between the second and fourth quarters of 2027. Other programs, such as an IL-31-containing bispecific for atopic dermatitis, are slated to enter the clinic in the second half of 2027.
Additional items to track include stockholder approvals for Series D preferred-stock conversion, any reverse stock split details, and filing of acquired-company financials and pro forma data. Broader biotech financing conditions, competition in immunology, and trial results will also shape sentiment. These elements bring both potential and risk that warrant close review. From what I see, I’m watching this closely for how the data unfolds.
In my research process, I often turn to Tickeron’s Trending AI Robots to review automated strategies that align with current market setups. The page curates top-performing bots from a larger suite, covering different approaches and timeframes so users can evaluate methodology and track records before applying them to names like BOLT. This helps surface data-driven ideas without replacing individual due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
BOLT saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned negative. In 98 of the 105 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The 10-day RSI Indicator for BOLT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 10 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Moving Average Convergence Divergence Histogram (MACD) for BOLT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
BOLT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BOLT crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
The 50-day moving average for BOLT moved above the 200-day moving average on November 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +61.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLT advanced for three days, in 156 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BOLT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 78 of 92 cases where BOLT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. BOLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.997) is normal, around the industry mean (3.498). P/E Ratio (-0.396) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.355) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology